Stocktoria
Compass Therapeutics, Inc. CMPX
Nasdaq · XNAS · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2020-11-13
Compass Therapeutics, Inc. statistics & valuation
Market cap$374.6M
P / B1.9×
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Operating margin | — | -6661.8% | — | — | — |
| Net margin | — | -5808.8% | — | — | — |
| FCF margin | — | -5282.2% | — | — | — |
| Return on assets | -30.3% | -35.2% | -27.1% | -19.6% | -53.4% |
| Return on equity | -33.8% | -39.4% | -28.6% | -21.6% | -58.7% |
| Debt / equity | — | — | — | — | 0.00× |
| Current ratio | 15.02 | 14.96 | 19.73 | 12.05 | 13.84 |
| Revenue growth | -100.0% | — | — | — | — |
Source: SEC EDGAR filings · CIK 0001738021 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.